Paul Anderson

Shares in Perth biotech Orthocell more than quadrupled in value today after the company released positive results from a trial of its nerve regeneration product.

Orthocell has capitalised on a sustained rally in its share price to raise $10.6 million via a share placement at 40 cents per share.

Bio-therapeutic company Orthocell has received commitments to raise $13 million from a share placement and up to a further $5 million from a share purchase plan, primarily to accelerate the commercialisation of its CelGro flagship product.

SPECIAL REPORT: As markets struggle under the pressure of the COVID-19 pandemic, the medtech industry has found itself with an unparalleled, if challenging, opportunity.

Perth-based biotherapeutic company Orthocell has received US approval for the use of its dental bone and tissue regeneration platform.

Perth-based Orthocell has struck a 25-year licensing and distribution agreement valued at $23.1 million with a major dental implant company.

Orthocell has reported a record revenue of $1.84 million in the recent quarter, with the biotech company’s annual growth up by more than 30 per cent.

Perth-founded biotech company Orthocell has received regulatory approval to commence sales of its guided bone regeneration product Striate+ in Canada.

Murdoch-based Orthocell has received regulatory approval to commence sales of Remplir in Singapore, as the listed biotech company posts a second consecutive quarter of record revenue.

Perth-based biotechnology firm Orthocell has raised $17 million to take its Remplir nerve regeneration product to the world's biggest healthcare market.

Orthocell has struck a deal with a medical equipment supply firm to distribute its nerve repair device in Singapore, sending the Perth company’s shares up 26 per cent.

Biotech firm Orthocell is a step closer to its nerve repair device Remplir being approved in the US, following the completion of its US regulatory study.

Orthocell has submitted its application for US Food and Drug Administration approval for its Remplir nerve regeneration product, marking another moment in a year full of milestones.

Murdoch-based regenerative medicine company Orthocell has posted its third consecutive quarter of record revenue, as it gears up for a final approval from the US FDA for its Remplir nerve product.

Kim Beazley-backed medtech company Orthocell has flagged an expedited expansion into several jurisdictions after strong early sales of its Remplir nerve repair technology.

Singapore’s Health Science Authority has granted regulatory approval for John Van Der Wielen-chaired Orthocell for use of its dental membrane project, Striate+.

Orthocell has received clearance from the US-based Food and Drug Administration to begin selling its nerve repair product Remplir in the country.

John Van Der Wielen-chaired Orthocell has received another timely boost, as it aims to further a push into Latin America.

Orthocell has posted its fourth consecutive quarter of record revenue, as the regenerative medicine company continues to expand its reach around the globe.